In vitro effects of quinine on the antibacterial activity of erythromycin against bacteria of clinical relevance

Oluremi Adejoke Akinwale, Uyi Oluwatobi Emokpae, Opeyemi Mariam Adebogun, Morenike Olutumbi Adeoye-Isijola and Olufunmiso Olusola Olajuyigbe *

Department of Microbiology, School of Science and Technology, PMB 4005, Babcock University, Ilisan-Remo, Ogun State, Nigeria.

GSC Biological and Pharmaceutical Sciences, 2021, 14(02), 077–086

Publication history: Received on 12 January 2021; revised on 08 February 2021; accepted on 10 February 2021

Article DOI: https://doi.org/10.30574/gscbps.2021.14.2.0033

Abstract
The study investigated the in vitro effects of quinine on the antibacterial activity of erythromycin for possible interactions. The antibacterial activities of each drug and their combinations were investigated by agar diffusion, agar and macrobroth dilution methods. While 100 µl of 1000 µg/ml of erythromycin produced inhibition zones ranging between 13 and 31 ± 1.0 mm in all the isolates except K. pneumoniae and P. aeruginosa ATCC 19582, combining the highest concentration of erythromycin with 35 µg/ml of quinine produced inhibition zones ranging between 14 and 34 ± 1.0 mm with the exception of S. flexneri KZN. Though quinine had no antibacterial effects on the isolates, erythromycin was effective at minimum inhibitory concentrations (MICs) ranging between 25 and 100 µg/ml while their combinations resulted in reduction of MICs of most of the isolates to 12.5 µg/ml except those against A. calcoaceticus anitratus CSIR, Ps. aeruginosa ATCC 15442, P. shigelloides ATCC 51903, A. hydrophila ATCC 35654, Ps. aeruginosa ATCC 19582 and E. faecalis KZN that remained unchanged in agar dilution. While the MICs of erythromycin ranged between 25 and 50 µg/ml, the MICs of this antibiotic was reduced to concentrations ranging between 12.5 and 50 µg/ml indicating 50% to 75% in the presence of quinine. The combination of erythromycin and quinine, in vitro, resulted in synergistic (50%), additive/indifference (44.44%) and antagonistic (11.11%) interactions while quinine at concentrations lower than plasma quinine concentrations was inhibitory to the antibacterial activity of erythromycin. The synergistic effect may serve as remedy for bacterial infections in which the test bacteria have been implicated.

Keywords: Antibacterial combination; Erythromycin; Resistance; Synergism; Quinine

1. Introduction
The increasing prevalence of drug-resistant bacteria as well as increased means of gaining resistance has made it crucial to explore and find alternative to antibacterial therapies. Consequently, drugs are combined to produce pharmacological effectiveness better than the anticipated effects of the drugs involved when used alone. Though the uses of drugs from one or more groups in combinations have been with the expectation of achieving therapeutic efficacies, the outcomes have not been without interactions. Drug interactions occur when the effect and/or concentration of a drug is modified by another substance in a concomitant treatment [1,2]. While a drug-drug interaction is a pharmacodynamic or pharmacokinetic influence of one drug on another to reduce the efficacy of one or both of the interacting drugs or to exacerbate other adverse effects of each other in nature [3], interactions may result in negative long-term outcomes and increased healthcare utilization and costs [4]. On the other hand, drug combinations resulting in synergistic interactions may increase efficacy while decreasing cytotoxicity by minimizing the required therapeutic doses [5].
Drug-drug interactions are actually quite common-place [6,7]. Although the incidence of adverse drug interactions caused by drug-drug interactions is modest [8,9], they are severe and, in most cases, lead to hospitalization [10]. They pose a risk of serious side effects to patients and are, also, among the leading cause of patient morbidity and mortality [11,12]. Although the percentage of potential drug-drug interactions resulting in adverse drug interactions ranged between 0% and 60% [13,14], polypharmacy resulting in drug-drug interactions account for 2.8% of hospital admission [15] and 3 – 5% of all in-hospital medication errors [16].

Erythromycin, the first macrolide antibiotic to be used clinically, is a metabolic product of *Streptococcus erythreus* [17]. It has chemical formula **C_{27}H_{47}O_{13}** [18], exhibit prokinetic effect [19] and reverse gastrostatic actions of antimotion sickness drugs [20]. Structurally, it contains a 14-membered lactone ring with ten asymmetric centres and two sugars (L-cladinose and D-desosamine) making it a compound very difficult to produce by synthetic methods due to the presence of ten stereo-specific carbons and several points of distinct substitution [21]. Erythromycin, acting as a motolin receptor agonist [22] and metabolized by enzymes of the cytochrome P450 system [23], is often prescribed to people allergic to penicillins [17] and not recommended when using clindamycin-containing products. The simultaneous usage of two erythromycin derivatives should be avoided as they possess a common mechanism of action [24]. Its combination with other drugs showed inhibition of carbazepine oxidation [25], changed pharmacokinetics and pharmacodynamics of midazolam [26] and had reduced antibacterial activity when combined with antacids [27]. While its *in vivo* interaction with quinine, a natural compound in *Cinchona* bark used in malaria endemic regions, against *Plasmodium falciparum* had been reported [28], there is a dearth of information on the *in vitro* influence of quinine on the antibacterial activity of erythromycin and possible interactions between the two drugs if co-administered in bacterial infections. This study, therefore, aimed at investigating the *in vitro* antibacterial activity of erythromycin alone and its combination with quinine for possible interactions which may be of clinically significant effect.

2. Material and methods

2.1. Bacterial culture and preparation of antibiotic solutions

The bacteria used in this study include Micrococcus luteus, *Pseudomonas aeruginosa* ATCC 15442, *Bacillus subtilis* KZN, *Plesiomonas shigelloides* ATCC 51903, *Aeromonas hydrophila* ATCC 35654, *Staphylococcus aureus* NCT 6571, *Escherichia coli* ATCC 25922, *Klebsiella pneumoniae* ATCC 10031, *Pseudomonas aeruginosa* ATCC 19582, *Klebsiella pneumoniae* ATCC 4352, *Proteus vulgaris* ATCC 6830, *Enterococcus faecalis* KZN, *Enterococcus faecalis* ATCC 29212, *Serratia marcescens* ATCC 9986, *Acinetobacter calcoaceticus* anitratus CSIR, *Shigella flexneri* ATCC 4352, *Enterococcus cloacae* ATCC 4352 and *Shigella sonnei* ATCC 29930. Pure antibiotic powders of erythromycin and quinine were used. The stock erythromycin and quinine solutions were prepared and dilutions made according to the manufacturer's recommendations.

2.2. Antibiotic susceptibility testing - agar diffusion method

Each bacterial strain's colony suspension was matched with 0.5 McFarland standards to give a resultant concentration of 1.5 × 10^7 cfu/ml. The antibiotic susceptibility testing was determined by swabbing the Mueller-Hinton agar (MHA) (Oxoids U.K) plates with the adjusted bacterial strains according to [29]. Agar wells were made with heat sterilized 6 mm cork borer before being filled with 100 μl of 250, 500 and 1000 μg/ml of erythromycin alone and 250 + 8.75, 500 + 17.5 and 1000 + 35 μg/ml of erythromycin combined with quinine taking care not to allow spillage of the solutions onto the agar surface. The plates, in duplicate, were allowed to stand for 1 h before being incubated at 37°C for 24 h. After incubation, the diameter of the inhibition zones produced by the antibiotic alone and those of its combination with quinine were measured in millimetres with a transparent rule and interpreted using the CLSI zone diameter interpretative standards [29]. Synergism was considered when combinations exhibited inhibition zones increment of 0.5 mm above those produced by the erythromycin alone.

2.3. Antibiotic susceptibility testing - agar dilution method

For the agar dilution assay, different concentrations (0.390 - 400) μg/ml of erythromycin and (0.093 – 200) μg/ml of quinine and their combinations were prepared in sterile Mueller Hinton agar maintained at 50°C. The antibiotic containing molten agar were gently agitated before being poured into sterile petri plates and allowed to solidify after which they were streaked with different isolates adjusted to 10^6 cfu/ml and incubated at 37°C for 24 h. The lowest concentration of erythromycin alone and those of its combination with quinine inhibiting the growth of the isolates were taken as the minimum inhibitory concentration.
2.4. Determination of minimal inhibitory concentrations (MICs)

To determine the MICs of erythromycin and quinine, 100 µl of each isolate was added to different concentrations (0.390 - 400) µg/ml of erythromycin and (0.093 - 200) µg/ml of quinine prepared by serial dilution in double strength Mueller Hinton broth. These concentration ranges were chosen on the basis that maximum macrolide serum concentrations ranged between 0.4 and 12 μg/ml [30] and plasma quinine concentrations ranged between 8 and 15 μg/ml [31]. To determine the effects of combining these drugs, each of the concentrations of the antibiotic and the quinine used in determining their MICs were combined before being inoculated with 100 µl of each of the bacterial strains and incubated at 37°C for 24 h. Blank Mueller Hinton broth was used as negative control. The MIC was defined as the lowest dilution that showed no growth in the Mueller Hinton broth. When the MICs of erythromycin in combination equal its MIC when used alone, the interactions were considered additive/indifference. When the MICs of erythromycin in combination were lower than its MICs when used alone, the interactions were considered synergistic. When the MICs of erythromycin in combination were higher than its MICs when used alone, the interactions were considered antagonistic.

2.5. Determination of minimum bactericidal concentrations (MBCs)

The minimum bactericidal concentration (MBC) is identified by determining the lowest concentration of antibacterial agent that reduced the viability of the initial bacterial inoculum by ≥99.9%. The MBC assays were carried out as described by Cheesbrough [32]. Here, antibiotic-free nutrient agar plates were inoculated with one loopful of culture taken from each of the first three broth cultures that showed no growth and the first growth-containing tube in the MIC tubes. The MBC plates were incubated at 37°C for 24 h. After the incubation periods, the lowest concentrations of erythromycin alone and its combination with quinine that did not produce bacterial growth on the solid medium were regarded as their MBC values. This observation was matched with the MIC test tube that did not show evidence of growth after 48 h of incubation.

3. Results

In this study, the inhibition zones produced by the erythromycin alone and its combination with quinine showed a concentration dependent antibacterial activity. With the exception of K. pneumoniae ATCC 4352 and P. aeruginosa ATCC 19582 which had no inhibition zones from erythromycin alone, the inhibition zones produced by the erythromycin alone ranged between 13 ± 1.0 mm and 31 ± 1.0 mm from 100 µl of 1000 µg/ml. Combining the highest concentration of erythromycin with 35 µg/ml, all the isolates had inhibition zones ranging between 14 ± 1.0 mm and 34 ± 1.0 mm exception S. flexneri KZN that was not susceptible. The interaction between erythromycin and quinine in combination were, therefore, considered synergistic. The drug combinations inhibited the tested organisms at high concentrations with S. aureus NCT 6571, E. coli ATCC 25922, S. marcescens ATCC 9986, M. luteus, S. flexneri KZN, K. pneumoniae ATCC 4352, P. aeruginosa ATCC 19582 and E. faecalis ATCC 29212 being the most resistant to erythromycin alone and its combination with 17.5 and 8.75 µg/ml quinine respectively (Table 1).
### Table 1 Zonal Inhibition (± 1.00 mm) produced by erythromycin alone and its combination with quinine

|                               | Erythromycin | Quinine | Erythromycin + Quinine |
|-------------------------------|--------------|---------|------------------------|
|                               | 1000 | 500 | 250 | 35 | 17.5 | 8.75 | 1000 + 35 | 500 + 17.5 | 250 + 8.75 |
| **Micrococcus luteus**        |      |      |      |    |      |      |          |            |            |
|                               | 16 ± 1.0 | 0 | 0 | 0 | 0 | 0 | 15 ± 1.0 | 0 | 0 |
| **Shigella flexneri KZN**     |      |      |      |    |      |      |          |            |            |
|                               | 13 ± 1.0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Bacillus subtilis KZN**     |      |      |      |    |      |      |          |            |            |
|                               | 14 ± 1.0 | 11 ± 1.0 | 0 | 0 | 0 | 0 | 15 ± 1.0 | 11 ± 1.0 | 0 |
| **Enterococcus faecalis KZN** |      |      |      |    |      |      |          |            |            |
|                               | 24 ± 1.0 | 21 ± 1.0 | 19 ± 1.0 | 0 | 0 | 0 | 24 ± 1.0 | 22 ± 1.0 | 20 ± 1.0 |
| **Proteus vulgaris ATCC 6830** |      |      |      |    |      |      |          |            |            |
|                               | 28 ± 1.0 | 26 ± 1.0 | 22 ± 1.0 | 0 | 0 | 0 | 26 ± 1.0 | 24 ± 1.0 | 21 ± 1.0 |
| **Shigella sonnei ATCC 29930** |      |      |      |    |      |      |          |            |            |
|                               | 25 ± 1.0 | 23 ± 1.0 | 20 ± 1.0 | 0 | 0 | 0 | 27 ± 1.0 | 26 ± 1.0 | 25 ± 1.0 |
| **Escherichia coli ATCC 25922** |      |      |      |    |      |      |          |            |            |
|                               | 15 ± 1.0 | 0 | 0 | 0 | 0 | 0 | 14 ± 1.0 | 0 | 0 |
| **Staphylococcus aureus NCT 6571** |      |      |      |    |      |      |          |            |            |
|                               | 15 ± 1.0 | 0 | 0 | 0 | 0 | 0 | 16 ± 1.0 | 0 | 0 |
| **Klebsiella pneumonia ATCC 4352** |      |      |      |    |      |      |          |            |            |
|                               | 0 | 0 | 0 | 0 | 0 | 0 | 14 ± 1.0 | 0 | 0 |
| **Klebsiella pneumoniae ATCC 10031** |      |      |      |    |      |      |          |            |            |
|                               | 31 ± 1.0 | 27 ± 1.0 | 25 ± 1.0 | 0 | 0 | 0 | 34 ± 1.0 | 28 ± 1.0 | 26 ± 1.0 |
| **Enterococcus faecalis ATCC 29212** |      |      |      |    |      |      |          |            |            |
|                               | 15 ± 1.0 | 0 | 0 | 0 | 0 | 0 | 16 ± 1.0 | 0 | 0 |
| **Enterobacter cloacae ATCC 13047** |      |      |      |    |      |      |          |            |            |
|                               | 31 ± 1.0 | 30 ± 1.0 | 28 ± 1.0 | 0 | 0 | 0 | 34 ± 1.0 | 29 ± 1.0 | 25 ± 1.0 |
| **Serratia marcescens ATCC 9986** |      |      |      |    |      |      |          |            |            |
|                               | 15 ± 1.0 | 0 | 0 | 0 | 0 | 0 | 16 ± 1.0 | 0 | 0 |
| **Aeromonas hydrophila ATCC 35654** |      |      |      |    |      |      |          |            |            |
|                               | 13 ± 1.0 | 12 ± 1.0 | 0 | 0 | 0 | 0 | 15 ± 1.0 | 13 ± 1.0 | 12 ± 1.0 |
| **Plesiomonas shigelloides ATCC 51903** |      |      |      |    |      |      |          |            |            |
|                               | 26 ± 1.0 | 22 ± 1.0 | 16 ± 1.0 | 0 | 0 | 0 | 24 ± 1.0 | 21 ± 1.0 | 20 ± 1.0 |
| **Pseudomonas aeruginosa ATCC 15442** |      |      |      |    |      |      |          |            |            |
|                               | 17 ± 1.0 | 15 ± 1.0 | 13 ± 1.0 | 0 | 0 | 0 | 18 ± 1.0 | 16 ± 1.0 | 13 ± 1.0 |
| **Pseudomonas aeruginosa ATCC 19582** |      |      |      |    |      |      |          |            |            |
|                               | 0 | 0 | 0 | 0 | 0 | 0 | 14 ± 1.0 | 0 | 0 |
| **Acinetobacter calcoceuticus anitratus CSIR** |      |      |      |    |      |      |          |            |            |
|                               | 15 ± 1.0 | 12 ± 1.0 | 0 | 0 | 0 | 0 | 16 ± 1.0 | 11 ± 1.0 | 0 |
The agar dilution assay for determining the antibacterial effects of erythromycin alone and its combination with quinine showed that quinine had no antibacterial activity on the isolates. However, while the isolates were susceptible to erythromycin alone at concentrations ranging between 25 and 100 µg/ml, its combination with quinine resulted in reduction of most of the concentrations to 12.5 µg/ml except those against *A. calcoaceticus anitratus* CSIR, *P. aeruginosa* ATCC 15442, *P. shigelloides* ATCC 51903, *A. hydrophila* ATCC 35654, *P. aeruginosa* ATCC 19582 and *E. faecalis* KZN that remained unchanged (Table 2).

**Table 2** Antibacterial activity of erythromycin alone and its combination with quinine by agar dilution assay

| Organisms                                | Erythromycin alone | Quinine alone | Erythromycin + Quinine |
|-------------------------------------------|--------------------|---------------|------------------------|
| Micrococcus luteus                        | 37.5               | 0             | 12.5/3.125             |
| *Shigella flexneri* KZN                   | 25                 | 0             | 12.5/3.125             |
| *Bacillus subtilis* KZN                   | 50                 | 0             | 12.5/3.125             |
| *Enterococcus faecalis* KZN               | 50                 | 0             | 50/12.5                |
| *Proteus vulgaris* ATCC 6830              | 37.5               | 0             | 12.5/3.125             |
| *Shigella sonnei* ATCC 29930              | 37.5               | 0             | 12.5/3.125             |
| *Escherichia coli* ATCC 25922             | 25                 | 0             | 12.5/3.125             |
| *Staphylococcus aureus* NCT 6571          | 25                 | 0             | 12.5/3.125             |
| *Klebsiella pneumonia* ATCC 4352          | 25                 | 0             | 12.5/3.125             |
| *Klebsiella pneumoniae* ATCC 10031        | 12.5               | 0             | 12.5/3.125             |
| *Enterococcus faecalis* ATCC 29212        | 25                 | 0             | 12.5/3.125             |
| *Enterobacter cloacae* ATCC 13047         | 25                 | 0             | 12.5/3.125             |
| *Serratia marcescens* ATTC 9986           | 25                 | 0             | 12.5/3.125             |
| *Aeromonas hydrophila* ATCC 35654         | 100                | 0             | 100/25                 |
| *Plesiomonas shigelloides* ATCC 51903     | 100                | 0             | 100/25                 |
| *Pseudomonas aeruginosa* ATCC 15442       | 50                 | 0             | 50/12.5                |
| *Pseudomonas aeruginosa* ATCC 19582       | 100                | 0             | 100/25                 |
| *Acinetobacter calcoaceticus anitratus* CSIR | 50             | 0             | 50/12.5                |

The MICs of erythromycin against all the isolates ranged between 25 and 50 µg/ml while the MBCs ranged between 50 and 100 µg/ml. The quinine did not have any antibacterial effect on test bacterial isolates at the different dilution concentrations. On combining the erythromycin with quinine, the MICs of erythromycin was reduced by 50% to 75% and ranged between 12.5 and 50 µg/ml. The reduction in the MICs showed that the combination of erythromycin and quinine, *in vitro*, resulted in synergistic, additive/indifference and antagonistic interactions. In a descending order, 50% of the interactions were synergistic, 44.44% was additive/indifference and 11.11% was antagonistic. While these interactions occurred when 3.125 µg/ml and 6.25 µg/ml of quinine were combined with 12.5 µg/ml and 25 µg/ml respectively, combining 0.15 and 0.5 µg/ml of quinine with the different concentrations of erythromycin resulted in antagonistic interactions and showed that quinine at concentrations lower than the plasma quinine concentrations would be inhibitory to the antibacterial activity of erythromycin (Table 3).
Table 3 Minimum inhibitory and bactericidal concentrations of erythromycin alone and its combination with quinine

| ORGANISM                          | Erythromycin alone | Quinine alone | Erythromycin + Quinine | Observed interactions | Erythromycin quinine + Erythromycin quinine |
|-----------------------------------|--------------------|---------------|------------------------|-----------------------|---------------------------------------------|
|                                   | MIC    | MBC | MIC    | MBC |                   |                                             |
| Micrococcus luteus                | 25     | 100 | 0      | 25/6.25 | 100/25          | Additive | 100 | 200 |
| Shigella flexneri KZN            | 50     | 100 | 0      | 50/12.5 | 100/25          | Additive | 200 | 100 |
| Bacillus subtilis KZN            | 25     | 50  | 0      | 50/12.5 | 100/25          | Antagonistic | 200 | 200 |
| Enterococcus faecalis KZN        | 25     | 50  | 0      | 25/6.25 | 100/25          | Additive | 200 | 200 |
| Proteus vulgaris ATCC 6830        | 25     | 50  | 0      | 25/6.25 | 100/25          | Synergy  | 200 | 200 |
| Shigella sonnei ATCC 29930        | 50     | 100 | 0      | 50/12.5 | 100/25          | Additive | 200 | <200 |
| Escherichia coli ATCC 25922       | 25     | 50  | 0      | 12.5/3.125 | 50/12.5          | Synergy  | 200 | 200 |
| Staphylococcus aureus NCT 6571    | 50     | 100 | 0      | 12.5/3.125 | 50/12.5          | Synergy  | 200 | 200 |
| Klebsiella pneumonia ATCC 4352    | 50     | 100 | 0      | 25/6.25 | 100/25          | Synergy  | 200 | <200 |
| Klebsiella pneumoniae ATCC 10031  | 25     | 50  | 0      | 25/6.25 | 100/25          | Additive | 200 | 200 |
| Enterococcus faecalis ATCC 29212  | 50     | 100 | 0      | 12.5/3.125 | 100/25          | Synergy  | 100 | <200 |
| Enterobacter cloacae ATCC 13047   | 50     | 100 | 0      | 12.5/3.125 | 100/25          | Synergy  | 200 | <200 |
| Serratia marcescens ATCC 9986     | 25     | 50  | 0      | 25/6.25 | 100/25          | Additive | 200 | 200 |
| Aeromonas hydrophila ATCC 35654   | 50     | 100 | 0      | 25/6.25 | 50/12.5          | Synergy  | 200 | 100 |
| Plesiomonas shigelloides ATCC 51903 | 25     | 50  | 0      | 12.5/3.125 | 50/12.5          | Synergy  | 200 | 200 |
| Pseudomonas aeruginosa ATCC 15442 | 50     | 100 | 0      | 12.5/3.125 | 100/25          | Synergy  | 200 | 200 |
| Pseudomonas aeruginosa ATCC 19582 | 25     | 100 | 0      | 25/6.25 | 100/25          | Additive | 200 | <200 |
| Acinetobacter calcoaceticus anitratus CSIR | 25     | 100 | 0      | 12.5/3.125 | 25/6.25          | Synergy  | 100 | 100 |
4. Discussion

The therapeutic use of antibiotics has been severely compromised by the emergence of drug resistance in many pathogenic bacteria. Hence, polypharmacy, in which drug combinations have been used for treating diseases and reducing sufferings, has been practiced and its use in modern therapeutics has increased. Although this is a common practice, investigating interactions of antibiotics with non-antimicrobial or antimalarial agents becomes essential because of the possible involvement of microbial infections in malaria.

In previous studies, the biochemical and pharmacological effects of antimicrobial agents combined with other drugs [33-36] and those of antimalarials prescribed along with antibiotics for the treatment of infectious diseases as well as their interactions in human have been reported [37,38]. While Khan et al. [39] indicated that combining amodiaquine and erythromycin was synergistic in three isolates of Plasmodium falciparum but antagonistic in five, Gershon and Howells [40] and Nakornchai and Konthiang [41] reported that interaction of erythromycin and chloroquine was synergistic against chloroquine resistant strain of P. falciparium in vitro. In in vivo assays, Pinichpongse et al. [42], Watt et al. [43] and Looareeesuwan et al. [44] indicated that tetracycline combined with quinine and mefloquine against multidrug resistant P. falciparum resulted in 83% to 100% cure rate while erythromycin combined with quinine had 80% rapid cure rate against P. falciparum [45].

Although in vitro studies on the effect of quinine and its interaction with erythromycin on bacteria is scarce, the antibacterial effects of combining erythromycin with quinine against bacteria, in this study, showed that there are interactions between these drugs. Combining erythromycin and quinine resulted in synergistic and additive/indifference interactions more than it being antagonistic. This agreed with Pieren and Tigges [46] who indicated that combination of antibiotics with other compounds not having antimicrobial activity can amplify the effect of an antibiotic. While Clancy and Nguyen [47] reported that combining amphotericin B with azithromycin resulted in synergy against resistant Fusarium, Oliver et al. [48] reported that the susceptibility of Candida albicans was increased when tetracycline was combined with amphotericin B. The additive and synergistic antibacterial effects of the combinations of quinine with erythromycin could, possibly, cause a higher cure rate or a more effective treatment against bacterial infections than would be obtained if erythromycin alone is used. This may be an addition to the current treatment of bacterial infections for which the isolates used have been implicated.

Since macrolides blocks protein synthesis by interacting with the ribosomal subunit [49] to inhibit translocation of peptidyl-tRNA from the receptor to the donor site and the initial steps of 50S subunit assembly [50], erythromycin and its different pro-drugs appear to be less potent inhibitors of drug metabolism [51]. However, while the effect of drug combinations could have resulted from different complex formations within the constituents of the respective drugs, the mechanism of action of the combined drugs could have resulted in complexation of their cationic groups with the phosphate groups of the nucleic acids, cell envelop damage and loss of structural integrity, blockade of RNA synthesis, interference with the cytochrome system and inhibition of oxygen consumption [52], arrest of DNA-dependent RNA synthesis [53], cellular energetic, ribosome binding and protein mistranslation [54] and inhibition of cell wall, DNA, RNA and protein synthesis [55]. The mechanism involved in synergisms could, also, be increased membrane permeability [56] and inhibition of a significant step in peptidoglycan assembly [57]. Thus, the synergistic effect may serve as remedy for urinary tract infection, acute bacterial diarrhea, chronic bronchitis and pneumonia seeing that synergy is a vital part of therapeutic efficacy [58].

5. Conclusion

The previous studies focused on the effects of combining erythromycin and chloroquine/quinine against malaria parasite in vivo, this study focused on the effect of combining erythromycin with quinine against bacterial isolates in vitro. The antibacterial potential of erythromycin combined with quinine and their synergistic effects are encouraging. However, when erythromycin and quinine are prescribed concurrently in patients with bacterial infections, a close monitoring of the blood concentrations of quinine may be required to avoid supra-therapeutic quinine concentrations that could lead to systemic toxicity. The synergistic and additive/indifference effects, in this study, indicated that combining erythromycin with quinine would be sufficient to treat some bacterial infections if properly managed.

Compliance with ethical standards

Disclosure of conflict of interest

The authors declare that we have no conflict of interest.
References

[1] Ereshefsky L, Dugan D. Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine. Depression and Anxiety. 2000; 12(Supp. 1): 30-44.

[2] Ereshefsky L, Jhee S, Grothe D. Antidepressant drug-drug interaction profile update. Drugs in R&D. 2005; 6(6): 323-336.

[3] Becker ML, Kallewaard M, Caspers PW, Schalekamp T, Stricker BH. Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Safety. 2005; 28(5): 371-378.

[4] Ereshefsky L. Antidepressant pharmacodynamics, pharmacokinetics and drug interactions. Geriatrics. 1998; 53(suppl. 4): S22-S33.

[5] Hall MJ, Duncan IB. Antiviral drug and interferon combinations. In: H.J Fields (ed), Antiviral Agents: The Development and Assessment of Antiviral Chemotherapy. 1988; II:29-84. CRC Press, Boca Raton, FL.

[6] Einarson TR, Metge CJ, Iskedjian M, Mukherjee J. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clinical Therapeutics. 2002; 24(12): 2126–2136.

[7] Juurlink DN, Mamdani M, Kopp A, Laupacis A, Redelmeier DA. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003; 289(13): 1652–1658.

[8] Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Striker BH. Hospitalizations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiology and Drug Safety. 2007; 16(6): 641-51.

[9] Leone R, Magro L, Moretti U, Catroneo P, Moschini M, Motola D, Taccori M, Conforti A. Identifying adverse drug reactions associated with drug-drug interactions: data mining of a spontaneous reporting database in Italy. Drug Safety. 2010; 33(8): 667-75.

[10] Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M. Adverse drug reactions in hospital inpatients: a prospective analysis of 3695 patient-episodes. PLoS ONE. 2009; 4(2): e4439.

[11] Alfaro CL. Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown. Psychopharmacology Bulletin. 2001; 35(4): 80–93.

[12] Yap YG, Camm AJ. Potential cardiac toxicity of H1-antihistamines. Clinical Allergy and Immunology. 2002; 17: 389–419.

[13] Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Safety. 2005; 28(1): 67-80.

[14] Astrand B, Astrand E, Antonov K, Petersson G. Detection of potential drug interactions - a model for a national pharmacy register. European Journal of Clinical Pharmacology. 2006; 62(9): 749-56.

[15] Shapiro LE, Shear NH. Drug-drug interactions: how scared should we be? CMAJ, 1999; 161(10): 1266-1267.

[16] Obreli Neto PR, Nobili A, de Lyra DP. Jr., Pilger D, Guidoni CM, de Oliveira Baldoni A, Cruciol-Souza JM, de Carvalho Freitas AL, Tettamanti M, Gaeti WP, Nakamura Cuman RK. Incidence and predictors of adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study. Journal of Pharmacy and Pharmaceutical Sciences. 2012; 15(2), 332-343.

[17] Parsad D, Pandhi R, Dogra S. A guide to selection and appropriate use of macrolides in skin infections. American Journal of Clinical Dermatology. 2003; 4(6): 389-397.

[18] Geo FB, Janet SB, Stephen AM, Jawetz Melnick and Adelberg’s. Medical Microbiology, Antibiotics Chemotherapy. McGraw Hill Company Inc. USA. 23rd eds. 2004; 170-2.

[19] Curry Jl, Lander TD, Stringer MD. Review article: Erythromycin as a prokinetic agent in infants and children. Alimentary Pharmacology and Therapeutics. 2001; 15(5): 595-603.

[20] Stewart JI, Wood MJ, Parish RC, Wood CD. Prokinetic effects of erythromycin after antimotion sickness drugs. Journal of Clinical Pharmacology. 2000; 40(4): 347-353.

[21] Pal S. A journey across the sequential development of macrolides and ketolides related to erythromycin. Tetrahedron. 2006; 62(14): 3171-3200.
Peeters T, Matthys G, Depoortere I, Cachet T, Hoogmartens J, Vantrappen G. Erythromycin is a motilin receptor agonist. American Journal of Physiology. 1989; 257(3 Pt 1): 470-4.

Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, Wright JT, Guzelian PS. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clinical Pharmacology and Therapeutics. 1992; 51(1): 18-23.

Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral Erythromycin and the Risk of sudden Death from Cardiac Causes. The New England Journal of Medicine. 2004; 351(11): 1089-96.

Branigan TA, Robbins RA, Cady WJ, Nickols JG, Ueda CT. The effects of erythromycin on the absorption and disposition kinetics of theophylline. European Journal of Clinical Pharmacology. 1981; 21(2): 115-120.

Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A. Influence of the antibiotic erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittelforschung. 1996; 46(2): 213-217.

Olajuyigbe OO, Adekola OO. In vitro interaction of erythromycin and polyvalent metallic ions (antacid) against clinical bacterial isolates. Pharmacologia. 2012; 3(7): 221-226.

Baird JK. Effectiveness of antimalarial drugs. The New England Journal of Medicine. 2005; 352(15): 1565-1577.

Clinical and Laboratory Standard Institute (CLSI): Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth informational supplement; M100-S18; Pennsylvania, PA, USA. 2008; 28(1): 46-52.

Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, Karlowsky WA. Review of macrolides and ketolides focuses on respiratory tract infections. Drugs. 2001; 61(4): 443-498.

White NJ. Drug treatment and prevention of malaria. European Journal of Clinical Pharmacology. 1988; 34: 1-14.

Cheesbrough M. District laboratory practice in tropical countries, 1st edn., Cambridge University Press, Cambridge, UK. 2006; 434.

Sultana N, Arayne MS, Ghazali FA. Effect of antacids on the dissolution behaviour of methacycline and doxycycline. Journal of the Pakistan Medical Association. 1984; 34: 59.

Olajuyigbe OO, Animashaun T. Synergistic activities of amoxicillin and erythromycin against bacteria of medical importance. Pharmacologia. 2012; 3(9): 450-455.

Olajuyigbe OO, Afolayan AJ. In vitro synergy and time-kill assessment of interactions between kanamycin and metronidazole against resistant bacteria. Tropical Journal of Pharmaceutical Research. 2015; 14(5): 837-843.

Olajuyigbe OO, Adeoye-Isisola MO, Adedayo O. Synergistic potentials of benzylpenicillin, amoxicillin and streptomycin antibiotics against selected bacterial species. Life Science Journal, 2016; 13(8): 37-44. https://doi.org/10.7537/marslsj130816.07

Padgham C, Richens A. Quinine metabolism as an index of hepatic drug-metabolizing capacity. British Society of Clinical Pharmacology, 1974; 1 (4): 352-53.

Fischer VW, Fitch CD. Affinity of chloroquine for bone. Journal of Pharmacy and Pharmacology. 1975; 27(7): 527-529.

Khan B, Brandling-Bennett AD, Watkins WM, Koech DK. Plasmodium falciparum sensitivity to erythromycin and 4-aminoquinoline combination in vitro. Annals of Tropical Medicine and Parasitology. 1991; 85(2): 215-220.

Gershon PD, Howells RE. Combination of the antibiotics erythromycin and tetracycline with three standard antimalarials against Plasmodium falciparum in vitro. Annals of Tropical Medicine and Parasitology. 1984; 78(1): 1-11.

Nakornchai S, Konthiang P. Activity of azithromycin or erythromycin in combination with antimalarial drugs against multidrug-resistant Plasmodium falciparum in vitro. Acta Tropica. 2006; 100(3): 185-191.

Pinichpongse S, Doberstyn EB, Cullen JR, Yisunsi L, Thongsombun Y, Thimasarn K. An evaluation of five regimens for the out-patient therapy of falciparum malaria in Thailand 1980-81. Bulletin of the World Health Organisation. 1982; 60: 907-912.

Watt G, Loesuttivibool I, Shanks GD, Boudreau EF, Brown AE, Pavanand K, Webster HK, Wechgritaya S. Quinine with tetracycline for the treatment of drug-resistant falciparum malaria in Thailand. American Journal of Tropical Medicine and Hygiene. 1992; 47(1): 108-111.
[44] Looareesuwan S, Vanijanonta S, Viravan C, Wilairatana P, Charoenlarp P, Lasserre R, Canfield C, Kyle DE, Webster HK. Randomised trial of mefloquine–tetracycline and quinine–tetracycline for acute uncomplicated falciparum malaria. Acta Tropica. 1994; 57(1): 47–53.

[45] Chongsuphajaisiddhi T, Sabchareon A, Attanath P. Treatment of quinine resistant falciparum malaria in Thai children. Southeast Asian Journal of Tropical Medicine and Public Health. 1983; 14: 357–362.

[46] Pieren M, Tigges M. Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance. Current Opinion in Pharmacology. 2012; 12(5): 551-555.

[47] Clancy CJ, Nguyen MH. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. Journal of Antimicrobial Chemotherapy. 1998; 41(1): 127-130.

[48] Oliver BG, Silver PM, Marie C, Hoot SJ, Leyde SE, White TC. Tetracycline alters drug susceptibility in *Candida albicans* and other pathogenic fungi. Microbiology. 2008; 154(Pt 3): 960-970.

[49] Garza RG, Xiong L, Zhong P, Mankin A. Binding site of macrolides antibiotics on the ribosomes; new resistance identifies a specific interaction of ketolides with rRNA. Bacteriology. 2001; 183(23): 6898-6907.

[50] Chitum HS, Champney WS. Erythromycin inhibits the assembly of the large ribosomal subunit in growing *Escherichia coli*. Current Microbiology. 1995; 30(5): 273-9.

[51] Abdelghaffar H, Soukri A, Babine-Chevaye C, Labro MT. Interaction of macrolides and ketolides with the phagocyte cell line PLB-985. Journal of Chemotherapy. 2003; 15(4): 350-356.

[52] Floss HG, Yu TW. Rifamycin-mode of action, resistance and biosynthesis. Chemical Reviews. 2005; 105(2): 621-632.

[53] Sultana N, Arayne MS. Drug antibiotic interactions-antimalarials. Journal of the Pakistan Medical Association. 1986; 36(2): 37-40.

[54] Vakulenko SB, Mobashery S. Versatility of aminoglycosides and prospects for their future. Clinical Microbiology Reviews. 2003; 16(3): 430-50.

[55] Straus SK, Hancock RE. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochimica Biophysica Acta. 2006; 1758(9): 1215-1223.

[56] Morones-Ramirez JR, Winkler J, Spina CS, Collins JJ. Silver enhances antibiotic activity against Gram-negative bacteria. Science Translational Medicine. 2013; 5(190): 190ra81.

[57] Olajuyigbe OO, Olajuyigbe AA, Afolayan AJ. Ultrastructure and X-ray microanalysis of the antibacterial effects of stem bark ethanol extract of *Acacia mearnsii* De Wild against Some Selected Bacteria, Journal of Pure and Applied Microbiology. 2018; 12(4): 2217-2228.

[58] Lin Y, Sun Z. Current views on type II diabetes. Journal of Endocrinology. 2010; 204(1): 1–11.